Central sleep apnea: Pathophysiology and treatment.

Central sleep apnea: Pathophysiology and treatment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Central sleep apnea: Pathophysiology and treatment. Abstract Text:

Danny J Eckert,Amy S Jordan,Pankaj Merchia,Atul Malhotra,Danny J Eckert,Amy S Jordan,Pankaj Merchia,Atul Malhotra,

Central sleep apnea (CSA) is characterized by a lack of drive to breathe during sleep, resulting in repetitive periods of insufficient ventilation and compromised gas exchange. These nighttime breathing disturbances can lead to important comorbidity and increased risk of adverse cardiovascular outcomes. There are several manifestations of CSA, including high altitude-induced periodic breathing, idiopathic CSA, narcotic-induced central apnea, obesity hypoventilation syndrome, and Cheyne-Stokes breathing. While unstable ventilatory control during sleep is the hallmark of CSA, the pathophysiology and the prevalence of the various forms of CSA vary greatly. This brief review summarizes the underlying physiology and modulating components influencing ventilatory control in CSA, describes the etiology of each of the various forms of CSA, and examines the key factors that may exacerbate apnea severity. The clinical implications of improved CSA pathophysiology knowledge and the potential for novel therapeutic treatment approaches are also discussed.

Central sleep apnea: Pathophysiology and treatment. Publishing Authors By Initials

DJ Eckert,AS Jordan,P Merchia,A Malhotra,DJ Eckert,AS Jordan,P Merchia,A Malhotra,

For similar respiratory tract diseases: respiration disorders: apnea: sleep apnea syndromes: sleep apnea, central research abstracts see: respiratory tract diseases: respiration disorders: apnea: sleep apnea syndromes: sleep apnea, central research

PUBMED ID PMID:

MEDLINE DATE:

Central sleep apnea: Pathophysiology and treatment. Journal Published:

PUBLICATION TYPE: Review

Journal: Chest

VOLUME: 131

Page Numbers: 595-607

Journal Abbreviation: Chest

ISSN: 0012-3692

DAY: 3

MONTH: Feb

YEAR: 2007

Central sleep apnea: Pathophysiology and treatment. Information

Number of References: 128

LANGUAGE: eng

NlmUniqueID: 231335

Central sleep apnea: Pathophysiology and treatment. Keywords Mesh Terms:

KEYWORDS: Sleep Apnea, Central

MESH TERMS: therapy

Chemical & Substance for Abstract: Central sleep apnea: Pathophysiology and treatment. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Central sleep apnea: Pathophysiology and treatment.

AFFILIATION: Division of Sleep Medicine, Sleep Disorders Program, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. deckert@rics.bwh.harvard.edu

Country: United States

AGENCY: United States NHLBI

GRANT: R01-HL73146-01

ACRONYM: HL

MEDLINETA: Chest

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Central sleep apnea: Pathophysiology and treatment Related Publications

• A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
• Anaesthetic considerations in a patient with wolff-Parkinson-white syndrome.
• Biosensor for total cholesterol estimation using N-(2-aminoethyl)-3-aminopropyltrimethoxysilane self-assembled monolayer.
• COMT genotype and manic symptoms in schizophrenia.
• COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance.
• Central sleep apnea: Pathophysiology and treatment.
• Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia.
• Corneal astigmatism with upper eyelid gold weight implantation using the combined high pretarsal and levator fixation technique.
• Cytokine release following recruitment maneuvers.
• DTNBP1 genotype influences cognitive decline in schizophrenia.
• Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits.
• Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia.
• Emotion-based decision-making in healthy subjects: short-term effects of reducing dopamine levels.
• Food vacuole targeting and trafficking of falcipain-2, an important cysteine protease of human malaria parasite Plasmodium falciparum.
• Genioglossus premotoneurons and the negative pressure reflex in rats.
• Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.
• Intense F-18 FDG uptake noted in a benign bone cyst.
• Loop around ear - a simple method for maintaining central venous line with ordinary venous cannula.
• Native manual tonsillectomy: A dangerous practice in Asir.
• Overexpression and purification of human calcitonin gene-related peptide-receptor component protein in Escherichia coli.
• Presumed fresh mutation hemophilia A presenting with subarachnoid hemorrhage in a newborn.
• Renal vein thrombosis: a case report.
• RluD, a highly conserved pseudouridine synthase, modifies 50S subunits more specifically and efficiently than free 23S rRNA.
• Scleral infiltration in orbitotemporal plexiform neurofibromatosis.
• The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations.
• The Golgi-associated protein GRASP is required for unconventional protein secretion during development.
• The future of pharmacotherapy for schizophrenia.
• The influence of aging on pharyngeal collapsibility during sleep.
• Upper airway myopathy is not important in the pathophysiology of obstructive sleep apnea.
• Use of computational modeling to predict responses to upper airway surgery in obstructive sleep apnea.